Next Article in Journal
Polyoxymethylene as Material for Removable Partial Dentures—A Literature Review and Illustrating Case Report
Previous Article in Journal
Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 10
Issue 7
10.3390/jcm10071457
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Postoperative Anemia Following Same-Day Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial

by
Man Soo Kim
1,
In Jun Koh
2,
Keun Young Choi
1,
Sung Cheol Yang
1 and
Yong In
1,*
1
Department of Orthopaedic Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea
2
Department of Orthopaedic Surgery, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 1021, Tongil Ro, Eunpyeong-gu, Seoul 03312, Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2021, 10(7), 1457; https://doi.org/10.3390/jcm10071457
Submission received: 1 March 2021 / Revised: 25 March 2021 / Accepted: 28 March 2021 / Published: 2 April 2021
(This article belongs to the Section Orthopedics)
Browse Figures
Versions Notes

Abstract

:
(1) Background: The purpose of this study was to evaluate the efficacy and safety of intravenous (IV) ferric carboxymaltose (FCM) to treat acute postoperative anemia following same-day bilateral total knee arthroplasty (TKA). (2) Methods: A total of 118 patients who underwent same-day bilateral TKA were randomly assigned to two groups: an FCM group (FCM infusion, 58 patients) and a Control group (placebo with normal saline, 60 patients). The primary endpoint was the number of responders with a Hb increase of two or more points by the second postoperative week. The secondary endpoints were Hb level, iron metabolism variables and blood transfusion rate at 2, 6 and 12 weeks after surgery. (3) Results: The FCM group had more Hb responders than the Control group (62.1% vs. 31.6%, p < 0.001). The Hb level was significantly higher in the FCM group during 12 weeks after surgery (all p < 0.05). Ferritin, iron and transferrin saturation levels were significantly higher in the FCM group from 2 to 12 weeks postoperatively (all p < 0.05). There was no difference in transfusion rate after surgery (p > 0.05). (4) Conclusion: In patients with postoperative anemia after same-day bilateral TKA, IV FCM infusion significantly improved Hb response two weeks after surgery without severe adverse events compared to placebo. In contrast, transfusion rate and various parameters of quality of life assessment up to 12 weeks did not vary between these groups. Level of evidence: Level I.

1. Introduction

After major surgery, the incidence of postoperative anemia is almost 90% [1]. During total knee arthroplasty (TKA), the risk of intraoperative bleeding is small because pneumatic tourniquets are generally used. However, more than 80% of total blood loss occurs within 24 h of TKA [2]. In addition, hidden blood loss accounts for approximately 50% of total blood loss [3]. Anemia in the perioperative period causes overall physical deterioration, such as fatigue, dizziness, reduced exercise tolerance or delayed recovery [4]. It also increases morbidity and mortality and negatively affects quality of life (QOL) [5,6]. Perioperative anemia has been associated with increased hospital stay and incidence of postoperative complications [5,6].
Various studies on preoperative anemia have been conducted. It is recommended that iron supplementation is used to correct anemia a few weeks prior to surgery [5,6]. However, there are few studies that have addressed iron supplementation for postoperative anemia [7]. In addition, it is burdensome and not always possible for patients who are scheduled for surgery to visit the hospital before surgery so that anemia can be identified and treated [8]. Furthermore, it is not possible to accurately predict which patients will develop postoperative anemia after TKA [9].
Intravenous (IV) ferric carboxymaltose (FCM) is an innovative IV iron formulation and stable iron complex that consists of a ferric hydroxide core stabilized by a nondextran carbohydrate shell [10]. FCM can be administered in a single, rapid session (15 min infusion) at large doses (15 mg/kg; maximum of 1000 mg/infusion) [10]. It has the advantage of being low risk with few gastrointestinal side effects [7]. Some studies have investigated the effect of IV FCM in the postoperative period after TKA [7,11,12]. However, no prior randomized controlled trial (RCT) has evaluated IV FCM as a treatment for anemia during the perioperative period in patients undergoing same-day bilateral TKA [13]. The purpose of this study was to evaluate the efficacy of IV FCM to treat acute postoperative anemia following same-day bilateral TKA. It was hypothesized that IV FCM would be an effective and safe treatment for postoperative anemia in patients undergoing same-day bilateral TKA.

2. Methods

A total of 134 cases of same-day bilateral TKAs were performed at our institution between March 2018 and May 2020. Among them, a prospective, randomized, patient-blinded, placebo-controlled study was performed on 120 patients with a Hb level <10 g/dL (from immediately after to 3 days after surgery). A total of 120 patients was randomly assigned to two groups. Fifty-eight patients were included in the FCM group (IV FCM infusion) after two patients were excluded due to periprosthetic joint infection and 60 patients in the Control group (Figure 1). This study was approved by the institutional review board at our hospital. All eligible subjects were informed of the standardized information on the clinical trial and provided written informed consent. The trial was registered with ClinicalTrials.gov (NCT03561480).
The study was conducted on patients with acute isovolemic anemia after same-day bilateral TKA. The definition of anemia is hemoglobin <12 g/dL in men or <13 g/dL in women. However, mild anemia was not included in this study [14]. Instead, we used Hb level <10 g/dL, which is a standard for moderate anemia, as the cut-off value [14]. The Hb level criterion used for transfusion is decreasing. In our study, the criterion for blood transfusion was strictly limited to cases with a Hb level <7 g/dL [15,16,17]. However, a Hb threshold of 8 g/dL was applied to patients with cardiovascular disease [18]. The preoperative exclusion criteria were hematologic disease, thromboembolic disease, hepatic or renal disease, coagulation disorder, infection, malignancy, anticoagulant therapy, hypersensitivity to iron and a history of a blood transfusion within the previous month, as well as an American Society of Anesthesiologists (ASA) grade of 3 or higher.
Randomization to receive FCM (FCM group) or placebo (Control group) was accomplished using the block randomization method to generate balanced groups. Randomization was performed using a method of sealed envelopes that contained information regarding procedure type. These envelopes were opened prior to the procedure. Because FCM is a typical dark brown color, both FCM and control treatments and IV lines were covered with black vinyl to ensure patient blinding.
The FCM group received 500 mg or 1000 mg of FCM, Ferinject® (Vifor Pharma, Flughofstrasse, Switzerland), according to body weight (1000 mg for body weight ≥50 kg or 500 mg for body weight <50 kg). The Control group received 200 or 100 mL of normal saline depending on body weight (0.9% sodium chloride solution; 200 mL for bodyweight ≥50 kg or 100 mL for body weight <50 kg) [19]. FCM was injected as a single IV infusion mixed with 100 mL of normal saline or as an undiluted bolus injection over an injection time of 15 min for 1000 mg or 6 min for 500 mg. The FCM and normal saline were injected only once. An antifibrinolytic drug was not used in this study.
The primary endpoint was the ratio of Hb responders at the second postoperative week. The minimally clinically important difference (MCID) of Hb change is generally accepted to be 2 g/dL [20,21]. A Hb responder was defined by an increase in Hb by 2 g/dL or more compared to baseline [14,22]. The baseline Hb level was that when FCM or normal saline was administered after surgery. The secondary endpoints were Hb level; iron metabolism variables of ferritin concentration, serum iron, total iron-binding capacity (TIBC) and transferrin saturation levels; the number of patients requiring blood transfusion; Brief Pain Inventory (BPI) and QOL scale scores using EQ-5D at 2 and 6 weeks and 3 months after surgery.
The Brief Pain Inventory (BPI) is widely used to measure patient pain intensity and the amount of disability in the functional aspects of daily life due to pain [23]. There are two categories of BPI: pain interference and pain intensity. Pain interference is divided into two categories of activity interference and affective interference. Activity interference involves general activities and the physical aspects of everyday life such as walking. Affective interference includes the emotional or internal aspects of everyday life, such as enjoyment and/or mood. Pain intensity is measured in four categories of worst, least, on average in the last 24 h and current, while pain interference is measured in seven categories of mood, work, general activity, walking, relationships, enjoyment of life and sleep. Patients rate each of these parameters on a scale of 0–10, where 10 means severe exacerbation of pain intensity and full interference to daily life. In the case of BPI pain intensity, the MCID is defined as a pain score change of 2.1–2.2 [24]. The MCID achievement of BPI pain intensity was also evaluated.
The EQ-5D is a commonly used and validated measurement tool for health-related QOL. It was developed by the EuroQol (EuroQ of Life) group and consists of five parts of mobility, self-care, daily activities, pain/discomfort and anxiety/depression. Each sector is measured using three grades of no problems, some problems, and extreme problems [25].
Safety and tolerability were continuously monitored during the three-month follow-up period. Symptoms and discomfort after FCM or saline injection were recorded. The side effects that occurred during the follow-up period were treated at the physician’s discretion. We also investigated whether there was a difference in length of hospital stay between the two groups.

Statistical Analysis

The target sample size was calculated for each group at a power of 80% to minimize the probability of a type II error. The alpha level of significance was set at 0.05. Because the MCID of Hb change was defined as 2 g/dL, the Hb responder was set to a change of Hb level of 2 g/dL or more [20,21]. The proportion of Hb responders 2 weeks after surgery was set as the primary outcome. The clinically meaningful important difference between Hb responders in the FCM and Placebo groups was set to 30%, in reference to the results of a previous study [22]. The estimated sample size was 44 patients for each group. Sixty patients were needed per group based on an estimate of 25% follow-up loss. Continuous variables were analyzed using a t-test, while categorical data were analyzed using a Chi-square test or Fisher’s exact test where appropriate for two independent samples. Descriptive analyses were based on frequency and percentage for categorical variables and mean and standard deviation for continuous variables. Hematologic markers including Hb and iron metabolism variables were assessed by repeated-measures analysis of variance test (ANOVA) and Bonferroni post hoc test to discover which specific means differed from one another. All statistical analyses were performed using SPSS ver. 21.0 program (SPSS Inc., Chicago, IL, USA). Values of p < 0.05 were considered statistically significant. Statistical analysis was performed from March 2018 to May 2020.

3. Results

There were 58 patients in the FCM group and 60 patients in the control group. There were no differences in demographic and hematologic laboratory findings between the two groups (Table 1). The postoperative Hb level did not vary between the two groups from immediately after surgery to three days postoperative (Figure 2) Two weeks after surgery, the FCM group had more Hb responders than the Control group (62.1% vs. 31.6%, p < 0.001). The Hb level was significantly improved at 2, 6 and 12 weeks after surgery compared to the postoperative baseline in both groups. Patients in the FCM group recovered preoperative Hb level at 12 weeks after surgery. However, patients in the Control group did not recover until 12 weeks postoperatively (Figure 2). After IV FCM was administered, Hb level was significantly higher in the FCM group than in the Control group at 2, 6 and 12 weeks after surgery (Figure 2, Table 2). Serum ferritin, iron and transferrin saturation was not significantly different between the two groups before surgery. However, these values were significantly higher in the FCM group than the Control group 2, 6 and 12 weeks after surgery (Table 2). There was no difference in TIBC level between the two groups before surgery; however, the Control group had a higher TIBC level than the FCM group until 12 weeks after surgery (Table 2).
The QOL measured by EQ 5D did not show any differences between the two groups preoperatively or at 2, 6 or 12 weeks postoperatively (Table 3). The BPI pain and BPI interference were similar between the two groups during the follow-up period (Table 4 and Figure 3). There was no significant difference in the achievement of MCID for BPI worst, least, average and right now pain levels between groups (all p > 0.05). The hospitalization period was not different between the two groups, with the FCM group being 7.2 days and the Placebo group 7.6 days (p > 0.05). Transfusion was performed within 3 days after surgery during the 12-week follow-up period. The Hb level at the time of transfusion was 6.6 ± 0.2 g/dL, and the median value was 6.7 g/dL. There was no significant difference between the FCM group and the Control group (11 cases, 19.3% vs. 13 cases, 21.7% respectively, p = 0.716).
There were three adverse events across both groups. Two adverse events of pruritus and headache occurred in the FCM group, while phlebitis occurred once in the Control group. No wound complications occurred in either group. All adverse events resolved uneventfully. Neither group had serious complications that required additional treatment (p > 0.05).

4. Discussion

The most important finding of this study was that postoperative IV FCM infusion significantly increased the proportion of Hb responders at two weeks after surgery. In addition, Hb level significantly increased in the FCM group compared to those in the Control group up to 12 weeks after surgery. Iron-related factors were also significantly higher in the Control group up to 12 weeks after surgery.
Various studies have been conducted on perioperative anemia in arthroplasty surgery [26,27]. There is interest in anemia after arthroplasty because it is mostly performed in the elderly and is associated with perioperative bleeding. However, most prior studies have focused on reducing transfusion requirements after surgery through the treatment of preoperative anemia. In addition, various guidelines have focused on improving clinical aspects through the correction of preoperative anemia [26,27]. Because most of the bleeding after arthroplasty occurs during the perioperative period [2,3], it is essential to know the effect of treatment on anemia during this period. However, although TKA is widely performed, there are little data regarding the treatment of postoperative anemia after TKA [7,8,11,12]. In particular, no studies have investigated the effect of IV FCM infusion in this setting, which is known to be an effective and stable option for iron deficiency anemia treatment. Therefore, a strength of this study is that it used a double-blind placebo-controlled RCT method to demonstrate the effect of FCM in same-day bilateral TKA.
This study was performed based on a Hb response threshold of 2 g/dL or more compared to baseline at two weeks after surgery. A 2 g/dL increase in Hb was set as a meaningful value [14,19,22]. Although Hb response is used as an important index to judge the effect of iron supplementation as a treatment for anemia, it has not been used in TKA-related studies [14,19,22]. One study used an increase in Hb level of 2 g/dL or more as a Hb response to examine the effect of IV FCM after surgery in another clinical setting [19,22]. In this study, there was a significantly higher percentage of Hb responders in the FCM group (62%) than in the placebo group (31%) [22]. In addition, the FCM group showed a significantly higher Hb level between 2 and 12 weeks postoperatively than the Control group. The FCM group also showed significantly superior results of all iron metabolism variables for up to three months.
If postoperative anemia persists, it can affect postoperative recovery and QOL [5,6]. Therefore, QOL and functional recovery after surgery were verified using the EQ 5D and BPI, There was no difference in QOL or BPI at 2, 6 or 12 weeks after surgery in the two groups. Most patients undergoing bilateral TKA are elderly and have a variety of comorbidities. However, a 12-week recovery period after bilateral TKA might be unable to adequately assess QOL. In fact, several studies also did not show differences between the FCM and control groups in QOL within a period of fewer than 12 weeks in elderly patients [11,22]. Therefore, a comparison of QOL between the two groups should be confirmed through large, longer-term studies [11].
In this study, there was no difference in the rate of transfusion between the two groups. The role of treatment for preoperative or postoperative anemia is important to reduce the transfusion rate after surgery [28]. In this study, IV FCM was administered when the Hb level was reduced to 10 g/dL or less following bilateral TKA. Transfusion was only performed between one and three days after surgery in both groups. In all cases of transfusion, IV FCM and placebo were administered before transfusion. In transfused patients with Hb of 7 g/dL or less, a large amount of blood loss after bilateral TKA occurred in the acute phase within three days after surgery. Therefore, this blood loss is not an appropriate outcome to accurately identify the effect of IV FCM because of the insufficient time for effective production [29]. The time to effect of IV FCM in practice is approximately one week [29,30]. Several studies comparing transfusion rates for postoperative anemia also showed no difference in transfusion rate [7,8].
Various side effects of IV iron supplementation have been reported. Prior reports have suggested that IV iron increases the risks of cardiovascular events [31], infection rates [32,33], and life-threatening hypersensitivity [34]. However, in this study, hypersensitivity, cardiovascular events and infection were not reported in either group. In addition, there was no difference in the proportion of side effects between the two groups. In the FCM group, pruritus appeared in one patient, and headache in another patient. One patient in the Control group developed phlebitis. IV FCM is a safe drug that is not associated with an increased risk of severe adverse events or infections [29,35], supporting the results of our study. The two FCM patients with side effects recovered without further abnormality.
Perioperative blood loss leads to a Hb decrease after surgery [28]. Inflammation induced by surgery also affects iron metabolism [36]. Hepcidin is a master regulator of iron metabolism that prevents the release of intracellular iron stores, inhibits iron uptake from the gut and reduces iron excretion into the blood [36,37]. Hepcidin is increased by inflammatory cytokines such as interleukin 6 [38]. This inflammatory reaction leads to functional iron deficiency anemia and consequently leads to iron-restricted erythropoiesis. After the administration of iron, reticulocytosis with erythropoiesis occurs to correct iron deficiency anemia [39]. IV FCM increases the possibility of using iron by providing sufficient iron refill [40] and increasing circulating iron [41]. Iron supplementation inhibits the production of TNF-a and promotes the recovery of hemoglobin [38].
This study has several limitations. First, most of the patients were female, and the study was conducted in one research institute. All patients in the current study were of Asian ethnicity. It is well known that a high proportion of OA in Asian patients occurs in women [42,43,44,45]. Given that this study was limited to Asian patients from one site, care must be taken when generalizing these results. Second, transfusion may be a confounding factor in determining the effect of FCM. All patients who underwent bilateral TKA and had a Hb level of 10 g/dL or less within three days after surgery were included. Blood transfusion was performed after IV FCM or placebo administration if baseline Hb was less than 7 g/dL. Therefore, changes in blood-related factors due to transfusion clearly could have interfered with the comparison of IV FCM and placebo groups. However, there was no difference in the rate of transfusion between the two groups. Third, the iron metabolism variable was measured three times after surgery. If these measurements also were performed on postoperative days 1–3, a clearer and more detailed longitudinal comparison of iron metabolism would have been possible between the two groups. However, we did not add this test because the enrolled subjects were targeted based on Hb level less than 10 g/dL after surgery and moderate isovolemic anemia [22]. Fourth, the economic effect of IV FCM was not considered in this study. Some studies have investigated the economic effects of IV FCM [46,47]. However, because the comparison of economic effects is determined according to the reimbursement policy of medical insurance in each country, it is difficult to compare clear cost effectiveness [46,47]. A longer follow-up of the effectiveness of FCM can give a clearer answer to the results of this study. Finally, it is difficult to confirm the safety of FCM and a lack of adverse events based on a study of only 60 patients. Although FCM has been approved for use in iron deficiency anemia patients, we plan to evaluate safety through a study with a larger number of patients. Despite these limitations, this study has a great advantage in being the first to compare the effect of postoperative IV FCM with placebo through prospective RCT in patients undergoing same-day bilateral TKA with a large amount of bleeding.

5. Conclusions

In patients with postoperative anemia after same-day bilateral TKA, IV FCM significantly improved Hb response at two weeks after surgery without significant adverse events compared to placebo. In contrast, transfusion rates and various parameters of QOL assessment up to 12 weeks did not vary between these two groups.

Author Contributions

Y.I. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: M.S.K., Y.I. Acquisition, analysis, or interpretation of data: M.S.K., I.J.K., K.Y.C., S.C.Y. Drafting of the manuscript: M.S.K., Y.I. Critical revision of the manuscript for important intellectual content: Statistical analysis: M.S.K., Y.I. Administrative, technical, or material support: M.S.K., I.J.K., K.Y.C., S.C.Y. Supervision: I.J.K., Y.I. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Seoul St. Mary’s Hospital (KC18OESI0256). The trial was registered with ClinicalTrials.gov (NCT03561480).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data collected for this study, including individual patient data, will not be made available.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gombotz, H.; Rehak, P.H.; Shander, A.; Hofmann, A. Blood use in elective surgery: The Austrian benchmark study. Transfusion 2007, 47, 1468–1480. [Google Scholar] [CrossRef]
  2. Senthil Kumar, G.; Von Arx, O.A.; Pozo, J.L. Rate of blood loss over 48 hours following total knee replacement. Knee 2005, 12, 307–309. [Google Scholar] [CrossRef]
  3. Sehat, K.R.; Evans, R.; Newman, J.H. How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account. Knee 2000, 7, 151–155. [Google Scholar] [CrossRef]
  4. Conlon, N.P.; Bale, E.P.; Herbison, G.P.; McCarroll, M. Postoperative anemia and quality of life after primary hip arthroplasty in patients over 65 years old. Anesth. Analg. 2008, 106, 1056–1061. [Google Scholar] [CrossRef]
  5. Clevenger, B.; Richards, T. Pre-operative anaemia. Anaesthesia 2015, 70 (Suppl. S1), 20–28. [Google Scholar] [CrossRef]
  6. Kotzé, A.; Harris, A.; Baker, C.; Iqbal, T.; Lavies, N.; Richards, T.; Ryan, K.; Taylor, C.; Thomas, D. British committee for standards in haematology guidelines on the identification and management of pre-operative anaemia. Br. J. Haematol. 2015, 171, 322–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Bisbe, E.; Moltó, L.; Arroyo, R.; Muniesa, J.M.; Tejero, M. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br. J. Anaesth. 2014, 113, 402–409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Park, H.S.; Kim, T.Y.; Kim, H.J.; Ro, Y.J.; Jang, H.Y.; Koh, W.U. The Effect of Intraoperative Ferric Carboxymaltose in Joint Arthroplasty Patients: A Randomized Trial. J. Clin. Med. 2019, 8, 1674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Hu, C.; Wang, Y.-H.; Shen, R.; Liu, C.; Sun, K.; Ye, L.; Ye, J.-J.; Yang, X.; Tian, S.-Q.; Yu, T.-B. Development and validation of a nomogram to predict perioperative blood transfusion in patients undergoing total knee arthroplasty. BMC Musculoskelet. Disord. 2020, 21, 315. [Google Scholar] [CrossRef] [PubMed]
  10. Lyseng-Williamson, K.A.; Keating, G.M. Ferric carboxymaltose: A review of its use in iron-deficiency anaemia. Drugs 2009, 69, 739–756. [Google Scholar] [CrossRef]
  11. Khalafallah, A.A.; Yan, C.; Al-Badri, R.; Robinson, E.; Kirkby, B.E.; Ingram, E.; Gray, Z.; Khelgi, V.; Robertson, I.K.; Kirkby, B.P. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: A prospective, open-label, randomised controlled trial. Lancet Haematol. 2016, 3, e415–e425. [Google Scholar] [CrossRef]
  12. Spahn, D.R. Anemia and patient blood management in hip and knee surgery: A systematic review of the literature. Anesthesiology 2010, 113, 482–495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Hadley, S.; Day, M.; Schwarzkopf, R.; Smith, A.; Slover, J.; Zuckerman, J. Is Simultaneous Bilateral Total Knee Arthroplasty (BTKA) as Safe as Staged BTKA? Am. J. Orthop. (Belle Mead N.J.) 2017, 46, E224–E229. [Google Scholar]
  14. Rizzo, J.D.; Brouwers, M.; Hurley, P.; Seidenfeld, J.; Somerfield, M.R.; Temin, S. American society of clinical oncology/american society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J. Oncol. Pract. 2010, 6, 317–320. [Google Scholar] [CrossRef]
  15. Liu, D.; Dan, M.; Martinez Martos, S.; Beller, E. Blood Management Strategies in Total Knee Arthroplasty. Knee Surg. Relat. Res. 2016, 28, 179–187. [Google Scholar] [CrossRef] [Green Version]
  16. Mufarrih, S.H.; Qureshi, N.Q.; Ali, A.; Malik, A.T.; Naim, H.; Noordin, S. Total knee Arthroplasty: Risk factors for allogeneic blood transfusions in the South Asian population. BMC Musculoskelet. Disord. 2017, 18, 359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Viberg, B.; Gundtoft, P.H.; Schønnemann, J.; Pedersen, L.; Andersen, L.R.; Titlestad, K.; Madsen, C.F.; Lauritsen, J.; Overgaard, S. Introduction of national guidelines for restrictive blood transfusion threshold for hip fracture patients—A consecutive cohort study based on complete follow-up in national databases. J. Orthop. Surg. Res. 2018, 13, 116. [Google Scholar] [CrossRef] [PubMed]
  18. Carson, J.L.; Guyatt, G.; Heddle, N.M.; Grossman, B.J.; Cohn, C.S.; Fung, M.K.; Gernsheimer, T.; Holcomb, J.B.; Kaplan, L.J.; Katz, L.M.; et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA 2016, 316, 2025–2035. [Google Scholar] [CrossRef]
  19. Evstatiev, R.; Marteau, P.; Iqbal, T.; Khalif, I.L.; Stein, J.; Bokemeyer, B.; Chopey, I.V.; Gutzwiller, F.S.; Riopel, L.; Gasche, C. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011, 141, e841–e842. [Google Scholar] [CrossRef]
  20. Eaton, C.B.; Hochberg, M.C.; Assaf, A.; Cryer, B.L.; Lu, B.; Sands, G.; Rodriguez, B.; LaCroix, A.; Lessin, L.; Limacher, M.C.; et al. The cross-sectional relationship of hemoglobin levels and functional outcomes in women with self-reported osteoarthritis: Results from the Women’s Health Initiative. Semin. Arthritis Rheum. 2011, 41, 406–414. [Google Scholar] [CrossRef] [Green Version]
  21. Strand, V.; Luo, X.; Bushmakin, A.; Cappelleri, J.; Assaf, A.; Cuffel, B. Effect of blood loss on physical functioning: Pooled analysis of patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum. 2009, 60, S318. [Google Scholar]
  22. Kim, Y.W.; Bae, J.M.; Park, Y.K.; Yang, H.K.; Yu, W.; Yook, J.H.; Noh, S.H.; Han, M.; Ryu, K.W.; Sohn, T.S.; et al. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients with Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial. JAMA 2017, 317, 2097–2104. [Google Scholar] [CrossRef]
  23. Williams, V.S.; Smith, M.Y.; Fehnel, S.E. The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. J. Pain Symptom Manag. 2006, 31, 48–57. [Google Scholar] [CrossRef]
  24. Mease, P.J.; Spaeth, M.; Clauw, D.J.; Arnold, L.M.; Bradley, L.A.; Russell, I.J.; Kajdasz, D.K.; Walker, D.J.; Chappell, A.S. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res. 2011, 63, 821–826. [Google Scholar] [CrossRef] [PubMed]
  25. Bilbao, A.; Martín-Fernández, J.; Arenaza, J.; García, I.; Tomás-García, N.; Trujillo-Martín, E.; García-Perez, L. Validation of the EQ-5D-5L in patients with hip or knee osteoarthritis. Value Health 2017, 20, A760. [Google Scholar] [CrossRef]
  26. Cuenca, J.; García-Erce, J.A.; Martínez, F.; Cardona, R.; Pérez-Serrano, L.; Muñoz, M. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int. J. Surg. 2007, 5, 89–94. [Google Scholar] [CrossRef] [Green Version]
  27. Gonzalez-Porras, J.R.; Colado, E.; Conde, M.P.; Lopez, T.; Nieto, M.J.; Corral, M. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus. Med. 2009, 19, 35–42. [Google Scholar] [CrossRef]
  28. Kim, S.K.; Seo, W.Y.; Kim, H.J.; Yoo, J.J. Postoperative Intravenous Ferric Carboxymaltose Reduces Transfusion Amounts after Orthopedic Hip Surgery. Clin. Orthop. Surg. 2018, 10, 20–25. [Google Scholar] [CrossRef] [PubMed]
  29. Moore, R.A.; Gaskell, H.; Rose, P.; Allan, J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011, 11, 4. [Google Scholar] [CrossRef] [Green Version]
  30. Ding, Y.; Zhu, X.; Li, X.; Zhang, H.; Wu, M.; Liu, J.; Palmen, M.; Roubert, B.; Li, C. Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia. Clin. Ther. 2020, 42, 276–285. [Google Scholar] [CrossRef] [Green Version]
  31. Zager, R.A.; Johnson, A.C.; Hanson, S.Y.; Wasse, H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am. J. Kidney Dis. 2002, 40, 90–103. [Google Scholar] [CrossRef] [PubMed]
  32. Fishbane, S. Review of issues relating to iron and infection. Am. J. Kidney Dis. 1999, 34, S47–S52. [Google Scholar] [CrossRef] [PubMed]
  33. Hill, G.E.; Frawley, W.H.; Griffith, K.E.; Forestner, J.E.; Minei, J.P. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: A meta-analysis. J. Trauma 2003, 54, 908–914. [Google Scholar] [CrossRef]
  34. Walters, B.A.; Van Wyck, D.B. Benchmarking iron dextran sensitivity: Reactions requiring resuscitative medication in incident and prevalent patients. Nephrol. Dial. Transplant. 2005, 20, 1438–1442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Avni, T.; Bieber, A.; Grossman, A.; Green, H.; Leibovici, L.; Gafter-Gvili, A. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin. Proc. 2015, 90, 12–23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Lasocki, S.; Longrois, D.; Montravers, P.; Beaumont, C. Hepcidin and anemia of the critically ill patient: Bench to bedside. Anesthesiology 2011, 114, 688–694. [Google Scholar] [CrossRef] [Green Version]
  37. Ganz, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102, 783–788. [Google Scholar] [CrossRef] [Green Version]
  38. Ganz, T. Anemia of inflammation. N. Engl. J. Med. 2019, 381, 1148–1157. [Google Scholar] [CrossRef] [PubMed]
  39. Wallis, J.P.; Wells, A.W.; Whitehead, S.; Brewster, N. Recovery from post-operative anaemia. Transfus. Med. 2005, 15, 413–418. [Google Scholar] [CrossRef]
  40. Kulnigg, S.; Stoinov, S.; Simanenkov, V.; Dudar, L.V.; Karnafel, W.; Garcia, L.C.; Sambuelli, A.M.; D’Haens, G.; Gasche, C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT®) randomized controlled trial. Am. J. Gastroenterol. 2008, 103, 1182–1192. [Google Scholar] [CrossRef]
  41. Na, H.S.; Shin, S.Y.; Hwang, J.Y.; Jeon, Y.T.; Kim, C.S.; Do, S.H. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion 2011, 51, 118–124. [Google Scholar] [CrossRef] [PubMed]
  42. Kim, C.W.; Lee, C.R. Effects of Femoral Lateral Bowing on Coronal Alignment and Component Position after Total Knee Arthroplasty: A Comparison of Conventional and Navigation-Assisted Surgery. Knee Surg. Relat. Res. 2018, 30, 64–73. [Google Scholar] [CrossRef] [Green Version]
  43. Kim, M.S.; Koh, I.J.; Choi, Y.J.; Kim, Y.D.; In, Y. Correcting Severe Varus Deformity Using Trial Components During Total Knee Arthroplasty. J. Arthroplast. 2017, 32, 1488–1495. [Google Scholar] [CrossRef] [PubMed]
  44. Kim, S.H.; Park, Y.B.; Song, M.K.; Lim, J.W.; Lee, H.J. Reliability and Validity of the Femorotibial Mechanical Axis Angle in Primary Total Knee Arthroplasty: Navigation versus Weight Bearing or Supine Whole Leg Radiographs. Knee Surg. Relat. Res. 2018, 30, 326–333. [Google Scholar] [CrossRef] [PubMed]
  45. Yoo, J.H.; Oh, H.C.; Park, S.H.; Kim, J.K.; Kim, S.H. Does Obesity Affect Clinical and Radiological Outcomes in Minimally Invasive Total Knee Arthroplasty? Minimum 5-Year Follow-up of Minimally Invasive TKA in Obese Patients. Clin. Orthop. Surg. 2018, 10, 315–321. [Google Scholar] [CrossRef]
  46. Basora, M.; Pereira, A.; Coca, M.; Tió, M.; Lozano, L. Cost-effectiveness analysis of ferric carboxymaltose in pre-operative haemoglobin optimisation in patients undergoing primary knee arthroplasty. Blood Transfus. 2018, 16, 438–442. [Google Scholar] [PubMed]
  47. Rognoni, C.; Ortalda, V.; Biasi, C.; Gambaro, G. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy. Adv. Ther. 2019, 36, 3253–3264. [Google Scholar] [CrossRef] [Green Version]
Jcm 10 01457 g001 550
Figure 1. Flow of patient enrollment, randomization and follow-up.
Figure 1. Flow of patient enrollment, randomization and follow-up.
Jcm 10 01457 g001
Jcm 10 01457 g002 550
Figure 2. Hemoglobin level from preoperative to postoperative 12 weeks.
Figure 2. Hemoglobin level from preoperative to postoperative 12 weeks.
Jcm 10 01457 g002
Jcm 10 01457 g003 550
Figure 3. Brief Pain Inventory (BPI) and pain intensity. Worst (a), least (b), average (c) and right now (d).
Figure 3. Brief Pain Inventory (BPI) and pain intensity. Worst (a), least (b), average (c) and right now (d).
Jcm 10 01457 g003
Table
Table 1. Baseline patient characteristics.
Table 1. Baseline patient characteristics.
CharacteristicsFerric Carboxymaltose
(n = 58)		Placebo
(n = 60)		p-Value
Age, mean (SD), y69.2 (4.7)70.3 (4.1)0.169
Sex 0.819
Male6 (10.3%)7 (11.7%)
Female52 (89.7%)53 (88.3%)
Body Mass Index, mean (SD)26.5 (3.8)27.2 (3.2)0.253
Comorbidities
Hypertension34 (58.6%)31 (51.7%)0.448
Diabetes12 (20.7%)8 (13.8%)0.287
Cardiovascular4 (6.9%)5 (8.3%)0.769
Brain0 (0%)3 (5.0%)0.085
Thyroid3 (5.2%)1 (1.7%)0.293
Kidney1 (1.7%)1 (1.7%)0.981
Lung4 (6.9%)2 (3.3%)0.378
Liver0 (0%)1 (1.7%)0.323
Smoking0 (0%)1 (1.7%)0.323
Alcohol1 (1.7%)0 (0%)0.307
ASA 0.082
118 (31.0%)28 (46.7%)
240 (69.0%)32 (53.3%)
Torniquet time Right, mean (SD), min41.2 (5.4)41.1 (6.3)0.926
Torniquet time Left, mean (SD), min42.0 (6.5)41.7 (6.4)0.822
Total Hemovac amount, mean (SD), mL811.5 (435.4)823.0 (348.8)0.878
Total blood loss during operation, mean (SD), mL369.7 (81.6)391.0 (85.2)0.168
Abbreviations: ASA, American Society of Anesthesiologists.
Table
Table 2. Hemoglobin and iron metabolism variables by group.
Table 2. Hemoglobin and iron metabolism variables by group.
Hematologic MarkersFerric Carboxymaltose
(n = 58)		Placebo
(n = 60)		p-Value
Hemoglobin, g/dL
Preoperative12.8 (1.1)13.1 (1.3)0.140
Postoperative 2 weeks11.2 (0.9)10.7 (1.0)0.007
Postoperative 6 weeks12.3 (0.8)11.8 (0.9)0.004
Postoperative 12 weeks13.1 (0.8)12.5 (1.1)0.007
Serum Ferritin, ng/mL
Preoperative108.6 (72.1)115.0 (73.5)0.641
Postoperative 2 weeks1191.8 (491.1)271.1 (226.6)<0.001
Postoperative 6 weeks753.4 (308.3)169.9 (145.9)<0.001
Postoperative 12 weeks475.0 (231.1)101.8 (98.2)<0.001
Iron, mcg/dL
Preoperative80.0 (32.5)82.6 (32.0)0.667
Postoperative 2 weeks86.8 (32.2)56.5 (22.7)<0.001
Postoperative 6 weeks80.0 (24.0)59.0 (23.3)<0.001
Postoperative 12 weeks83.4 (25.3)60.7 (21.7)<0.001
Total Iron-Binding Capacity, mcg/dL
Preoperative318.1 (46.9)317.6 (60.2)0.961
Postoperative 2 weeks269.2 (39.2)292.6 (44.8)0.004
Postoperative 6 weeks250.8 (34.6)306.0 (54.7)<0.001
Postoperative 12 weeks255.4 (33.5)320.3 (57.6)<0.001
Transferrin Saturation, %
Preoperative25.6 (11.2)27.1 (10.8)0.497
Postoperative 2 weeks32.7 (12.8)19.9 (8.6)<0.001
Postoperative 6 weeks32.0 (9.6)19.9 (8.4)<0.001
Postoperative 12 weeks32.4 (9.0)19.9 (8.8)<0.001
Table
Table 3. Quality of life assessment using the EQ 5D.
Table 3. Quality of life assessment using the EQ 5D.
EQ-5DFerric Carboxymaltose
(n = 58)		Placebo
(n = 60)		p-Value
EQ 5D-1 Mobility
Preoperative1.9 (0.4)1.9 (0.4)0.834
Postoperative 2 weeks2.0 (0.5)1.9 (0.4)0.680
Postoperative 6 weeks1.8 (0.4)1.8 (0.4)0.451
Postoperative 12 weeks1.7 (0.5)1.6 (0.5)0.482
EQ 5D-2 Self-Care
Preoperative1.5 (0.6)1.4 (0.6)0.830
Postoperative 2 weeks1.9 (0.6)1.8 (0.5)0.884
Postoperative 6 weeks1.8 (0.4)1.8 (0.5)0.775
Postoperative 12 weeks1.5 (0.6)1.6 (0.6)0.449
EQ 5D-3 Usual Activities
Preoperative1.7 (0.5)1.7 (0.6)0.903
Postoperative 2 weeks2.1 (0.4)2.1 (0.5)0.982
Postoperative 6 weeks1.8 (0.4)1.8 (0.5)0.528
Postoperative 12 weeks1.6 (0.6)1.7 (0.7)0.564
EQ 5D-4 Pain/Discomfort
Preoperative2.2 (0.6)2.2 (0.0)0.418
Postoperative 2 weeks2.0 (0.3)1.9 (0.3)0.750
Postoperative 6 weeks1.9 (0.5)2.0 (0.6)0.309
Postoperative 12 weeks1.6 (0.6)1.4 (0.5)0.076
EQ 5D-5 Anxiety/Depression
Preoperative1.5 (0.6)1.4 (0.5)0.453
Postoperative 2 weeks1.5 (0.5)1.5 (0.5)0.778
Postoperative 6 weeks1.5 (0.5)1.5 (0.5)0.628
Postoperative 12 weeks1.7 (0.5)1.7 (0.5)0.616
Table
Table 4. Brief Pain Inventory (BPI) and pain interference.
Table 4. Brief Pain Inventory (BPI) and pain interference.
BPI InterferenceFerric Carboxymaltose
(n = 58)		Placebo
(n = 60)		p-Value
BPI Interference General Activity
Preoperative6.4 (2.6)6.2 (1.8)0.639
Postoperative 2 weeks6.5 (1.8)5.9 (1.8)0.150
Postoperative 6 weeks5.1 (1.5)4.7 (1.1)0.157
Postoperative 12 weeks4.2 (1.3)4.1 (1.1)0.689
BPI Interference Walking
Preoperative6.0 (2.6)6.0 (1.9)0.868
Postoperative 2 weeks6.1 (1.9)5.9 (1.9)0.645
Postoperative 6 weeks5.3 (1.5)4.8 (1.3)0.125
Postoperative 12 weeks4.5 (1.5)4.2 (1.4)0.456
BPI Interference Work
Preoperative6.3 (2.1)6.1 (1.9)0.695
Postoperative 2 weeks6.2 (2.1)6.0 (1.8)0.522
Postoperative 6 weeks5.3 (1.5)4.8 (1.4)0.108
Postoperative 12 weeks4.4 (1.4)4.3 (1.3)0.735
BPI Interference Sleep
Preoperative5.5 (2.7)5.2 (2.3)0.498
Postoperative 2 weeks5.5 (2.2)5.1 (2.1)0.340
Postoperative 6 weeks4.6 (1.6)4.1 (1.4)0.098
Postoperative 12 weeks3.9 (1.4)3.8 (1.4)0.991
BPI Interference Relation
Preoperative5.3 (2.8)5.0 (2.5)0.557
Postoperative 2 weeks5.1 (2.6)4.9 (2.2)0.659
Postoperative 6 weeks4.3 (1.9)4.1 (1.7)0.593
Postoperative 12 weeks3.5 (1.5)3.8 (1.6)0.439
BPI Interference Enjoyment
Preoperative5.7 (2.5)5.6 (2.1)0.810
Postoperative 2 weeks5.7 (2.1)5.5 (1.9)0.697
Postoperative 6 weeks4.9 (1.3)4.7 (1.5)0.517
Postoperative 12 weeks4.0 (1.3)4.2 (1.4)0.591
BPI Interference Mood
Preoperative5.8 (2.8)5.4 (2.2)0.488
Postoperative 2 weeks6.0 (2.3)5.5 (2.1)0.284
Postoperative 6 weeks5.0 (2.0)4.4 (1.4)0.084
Postoperative 12 weeks4.3 (1.7)4.0 (1.4)0.366
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kim, M.S.; Koh, I.J.; Choi, K.Y.; Yang, S.C.; In, Y. Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Postoperative Anemia Following Same-Day Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial. J. Clin. Med. 2021, 10, 1457. https://doi.org/10.3390/jcm10071457

AMA Style

Kim MS, Koh IJ, Choi KY, Yang SC, In Y. Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Postoperative Anemia Following Same-Day Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial. Journal of Clinical Medicine. 2021; 10(7):1457. https://doi.org/10.3390/jcm10071457

Chicago/Turabian Style

Kim, Man Soo, In Jun Koh, Keun Young Choi, Sung Cheol Yang, and Yong In. 2021. "Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Postoperative Anemia Following Same-Day Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial" Journal of Clinical Medicine 10, no. 7: 1457. https://doi.org/10.3390/jcm10071457

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop